Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study

Blood (2024) 144 (Supplement 1): 988.

https://doi.org/10.1182/blood-2024-194328

Published: 2024

Journal Articles

Repurposing of the Iron Chelator Deferasirox to Overcome Venetoclax Resistance in Mantle Cell Lymphoma Via Downregulation of MCL1

Saar Shapira, Aladin Samara, Ronit Gurion, Anat Gafter-Gvili, Pia Raanani, Galit Granot

Blood (2024) 144 (Supplement 1): 5765.

https://doi.org/10.1182/blood-2024-202600

Published: 2024

Journal Articles

Epcoritamab for Relapsed/Refractory B Cell Lymphoma - the Israeli Real-World Experience of a Compassionate Use Program

Shlomzion Aumann, Abraham Avigdor, Ronit Marcus, Netanel A. Horowitz, Ronit Gurion, Tamar Tadmor, Roy Vitkon, May Meira Basood, Uri Abadi, Meirav Kedmi

Blood (2024) 144 (Supplement 1): 5124.

https://doi.org/10.1182/blood-2024-198926

Published: 2024

Journal Articles

Infectious Complications in CLL/SLL Patients Receiving Bruton Tyrosine Kinase Inhibitors- Systematic Review and Meta-Analysis of Randomized Controlled Trials

Shira Buchrits, Odil Giladi, Gal Trieman, Liron Hofstetter, Ronit Gurion, Galit Granot, Adi Shacham Abulafia, Pia Raanani, Anat Gafter-Gvili

Blood (2024) 144 (Supplement 1): 6777.

https://doi.org/10.1182/blood-2024-208263

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial

Ronit Gurion, Irit Avivi Mazza, Catherine Thieblemont, Won Seog Kim, Andras Masszi, Alejandro Martín García-Sancho, Zsolt Nagy, Benoit Tessoulin, Ana Jimenez Ubieto, Po-Shen Ko, Daniel Alan Kerr, II, Edwin E. Jeng, Satya Siddani, Neha Joshi, Neha Dixit, Mariana Sacchi, Pegah Jafarinasabian, Abraham Avigdor

Blood (2024) 144 (Supplement 1): 3110.

https://doi.org/10.1182/blood-2024-199301

Published: 2024

Journal Articles

Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma - International, Multi-Center Real-World Experience

Efrat Luttwak, Swetha Kambhampati, Esther Drill, Nivetha Ganesan, Liron Hofstetter, Ronit Gurion, Shlomzion Aumann, Arnon Haran, Mika Geva, Marc Panossian, Robert Stuver, Paul A. Hamlin, Ariela Noy, Alex F. Herrera, Alison Moskowitz

Blood (2024) 144 (Supplement 1): 1668.

https://doi.org/10.1182/blood-2024-212085

Published: 2024

Journal Articles

Warburg-Effect Driven Lactic Acidosis Is Associated with Early Death in Patients with Lymphoma

Bahaa Atamna, Alon Rozental, Mohamed Haj Yahia, Ronit Gurion, Moshe Yeshurun, Pia Raanani, Ofir Wolach

Blood (2024) 144 (Supplement 1): 4476.

https://doi.org/10.1182/blood-2024-208234

Published: 2024

Journal Articles

Warburg-Effect Driven Lactic Acidosis Is Associated with Early Death in Patients with Lymphoma

Bahaa Atamna, Pia Raanani, Ronit Gurion, Ofir Wolach

Blood (2023) 142 (Supplement 1): 6307.

https://doi.org/10.1182/blood-2023-187265

Published: 2023

Journal Articles

Efficacy and Safety of Glofitamab in Patients with R/R DLBCL in Real Life Setting - a Retrospective Study

Ronit Gurion, Dmitri Guz, Meirav Kedmi, Chava Perry, Irit Avivi Mazza, Netanel A. Horowitz, Uri Abadi, Anat Gafter-Gvili, Pia Raanani, Neta Goldschmidt, Boaz Nachmias, Shlomzion Aumann

Blood (2023) 142 (Supplement 1): 5170.

https://doi.org/10.1182/blood-2023-186033

Published: 2023

Journal Articles

Efficacy of Luspatercept in Low-Risk Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis

Irina Amitai, Ronit Gurion, Pia Raanani, Moshe Yeshurun, Ofir Wolach, Drorit Merkel, Yoav Amitai, Anat Gafter-Gvili, Liat Shargian

Blood (2023) 142 (Supplement 1): 6487.

https://doi.org/10.1182/blood-2023-189891

Published: 2023

Journal Articles

Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society

Blood (2023) 142 (Supplement 1): 2537.

https://doi.org/10.1182/blood-2023-188829

Published: 2023

Journal Articles

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 4460.

https://doi.org/10.1182/blood-2023-174213

Published: 2023

Journal Articles

Deep Proteomic Analysis Reveals Shared Terminal Mechanisms for Familial Hemophagocytic Lymphohistiocytosis and Lymphoma-Associated Hyperinflammation

Adi Zoref-Lorenz, Uri Abadi, Ronit Gurion, Alexander Osnis, Joanne Yacobovich, Yehudit Birger, Galit Berger Pinto, Pia Raanani, Arnon Nagler, Shai Dulberg, Asaf Madi, Gilad Itchaki, Martin H. Ellis, Shai Izraeli, Michael B. Jordan

Blood (2023) 142 (Supplement 1): 677.

https://doi.org/10.1182/blood-2023-189849

Published: 2023

Journal Articles

Second Vs Third Line Treatment with Axicabtagene Ciloleucel for Large B Cell Lymphoma - a Real-Life National Multicenter Retrospective Cohort Study with Propensity Score Matching

Gil Fridberg, Odelia Amit, Liat Shargian, Ofrat Beyar Katz, Sigal Grisariu, Chava Perry, Ronit Gurion, Batia Avni, Tsila Zuckerman, Irit Avivi Mazza, Ron Ram

Blood (2023) 142 (Supplement 1): 4886.

https://doi.org/10.1182/blood-2023-188473

Published: 2023

Journal Articles

Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era

Theodoros P. Vassilakopoulos, Fotios Panitsas, Zois Mellios, John Apostolidis, Alexia Piperidou, Michalis D Michael, Ronit Gurion, Meltem Akay, Eleftheria Hatzimichael, Stamatis J. Karakatsanis, Maria Dimou, Christina Kalpadakis, Eirini Katodritou, Theoni Leonidopoulou, Ioannis Kotsianidis, Chara Giatra, Nikolaos Kanellias, Ayman Sayyed, Tamar Tadmor, Leylagul Kaynar, Miri Zektser, Argiris Symeonidis, SC Atalar, Evgenia Verrou, Odit Gutwein, Chezi Ganzel, Giorgos Karianakis, Jonathan Isenberg, Gabriela Gainaru, Theodora Triantafyllou, Efimia Vrakidou, Maria Palassopoulou, Mehmet Ozgur, Semra Paydas, Panagiotis Tsirigotis, Maria Tsirogianni, Tulin Tuglular, Chrysovalantou Chatzidimitriou, Maria Kotsopoulou, Evangelos Terpos, Panagiotis Zikos, Argyro Koumarianou, Christos Poziopoulos, Dimitrios Boutsis, Anat Gafter-Gvili, Themistoklis Karmiris, Maria K. Angelopoulou, Maria Bakiri Papaioannou, Gerassimos Pangalis, Panayiotis Panayiotidis, Burhan Ferhanoglu, Netanel A. Horowitz, Sotirios Papageorgiou

Blood (2022) 140 (Supplement 1): 9554–9556.

https://doi.org/10.1182/blood-2022-168627

Published: 2022

Journal Articles

The Optimized HLH Inflammatory Index Is Associated with a Higher Stage of Lymphoma, but an Unexpected High Mortality Associated with Inflammation

Blood (2022) 140 (Supplement 1): 8326–8328.

https://doi.org/10.1182/blood-2022-170790

Published: 2022

Journal Articles

Obinutuzumab Versus Rituximab Based First-Line Chemoimmunotherapy for Follicular Lymphoma - a Real-World Multicenter Retrospective Cohort Study

Tamar Berger, Tzippy Shochat, Shlomzion Aumann, Boaz Nachmias, Neta Goldschmidt, Nurit Horesh, Reut Harel, Ariel Aviv, Ella Shmerts, Uri Abadi, Pia Raanani, Anat Gafter-Gvili, Ronit Gurion

Blood (2022) 140 (Supplement 1): 11947–11948.

https://doi.org/10.1182/blood-2022-159881

Published: 2022

Journal Articles

A Comprehensive Toxicity and Efficacy Analysis of Different Bridging Therapies Prior to Anti CD19-CAR-T Cell Therapy in Patients with DLBCL- a National Multi-Center Cohort Study

Ron Ram, Sigal Grisariu, Liat Shargian-Alon, Dana Yehudai-Ofir, Irit Avivi, Orit Gutfeld, Polina Stepensky, Tsila Zuckerman, Moshe Yeshurun, Odelia Amit, Batia Avni, Ronit Gurion, Yael Bar-On, Ofrat Beyar-Katz, Ronit Gold, Shimrit Ringelstein, Itai Levi, Tzvi Porges, Chava Perry

Blood (2021) 138 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2021-151085

Published: 2021

Journal Articles

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)

Tycel Phillips, Abraham Avigdor, Ronit Gurion, Caterina Patti, Paolo Corradini, Monica Tani, Amitkumar Mehta, Izidore S. Lossos, Pier Luigi Luigi Zinzani, Catherine Thieblemont, Wojciech Jurczak, Fred Zheng, Erica Rappold, Wanying Zhao, Peter Johnson

Blood (2021) 138 (Supplement 1): 44.

https://doi.org/10.1182/blood-2021-147778

Published: 2021

Journal Articles

Effect of Steroid Treatment on the Diagnostic Yield of Baseline PET CT in Aggressive B Cell Lymphoma

Karyn Revital Geiger, Oren Pasvolsky, Tamar Berger, Pia Raanani, Tzippy Shochat, Ronit Gurion, Tamar Anati, David Groshar, Anat Gafter-Gvili, Hanna Bernstine

Blood (2021) 138 (Supplement 1): 1453.

https://doi.org/10.1182/blood-2021-146118

Published: 2021

NARROW

Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study

Repurposing of the Iron Chelator Deferasirox to Overcome Venetoclax Resistance in Mantle Cell Lymphoma Via Downregulation of MCL1

Epcoritamab for Relapsed/Refractory B Cell Lymphoma - the Israeli Real-World Experience of a Compassionate Use Program

Infectious Complications in CLL/SLL Patients Receiving Bruton Tyrosine Kinase Inhibitors- Systematic Review and Meta-Analysis of Randomized Controlled Trials

Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial

Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma - International, Multi-Center Real-World Experience

Warburg-Effect Driven Lactic Acidosis Is Associated with Early Death in Patients with Lymphoma

Warburg-Effect Driven Lactic Acidosis Is Associated with Early Death in Patients with Lymphoma

Efficacy and Safety of Glofitamab in Patients with R/R DLBCL in Real Life Setting - a Retrospective Study

Efficacy of Luspatercept in Low-Risk Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis

Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

Deep Proteomic Analysis Reveals Shared Terminal Mechanisms for Familial Hemophagocytic Lymphohistiocytosis and Lymphoma-Associated Hyperinflammation

Second Vs Third Line Treatment with Axicabtagene Ciloleucel for Large B Cell Lymphoma - a Real-Life National Multicenter Retrospective Cohort Study with Propensity Score Matching

Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era

The Optimized HLH Inflammatory Index Is Associated with a Higher Stage of Lymphoma, but an Unexpected High Mortality Associated with Inflammation

Obinutuzumab Versus Rituximab Based First-Line Chemoimmunotherapy for Follicular Lymphoma - a Real-World Multicenter Retrospective Cohort Study

A Comprehensive Toxicity and Efficacy Analysis of Different Bridging Therapies Prior to Anti CD19-CAR-T Cell Therapy in Patients with DLBCL- a National Multi-Center Cohort Study

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)

Effect of Steroid Treatment on the Diagnostic Yield of Baseline PET CT in Aggressive B Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only